Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

  • By

  • Benoit Peyronnet

  • Benjamin M. Brucker

  • Cosimo De Nunzio

  • Christian Gratzke

  • John Heesakkers

  • Martin C. Michel

  • Maurizio Serati

  • David Staskin

  • Christopher Chapple

  • November 3, 2025

Share

Objective:

To correct the publication of an incorrect figure in the original article regarding Vibegron.

Key Findings:
  • The original article contained an error in the publication of Fig. 1.
  • The corrected figure has been provided in the updated article.
Interpretation:

The correction ensures that readers have access to accurate visual data related to Vibegron in the context of overactive bladder.

Limitations:
  • No new data or findings were introduced in the correction.
Conclusion:

The original article has been amended to reflect the correct figure, maintaining the integrity of the research.

Original Source(s)

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

  • by Benoit Peyronnet, Benjamin M. Brucker, Cosimo De Nunzio, Christian Gratzke, John Heesakkers, Martin C. Michel, Maurizio Serati, David Staskin, Christopher Chapple

  • November 3, 2025

Related Content

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

Second Primary Cancer Risk Shifts Over Time

US registry study finds overall declines but rising risk in lung, melanoma, and older survivor groups

Thulium fiber vs. holmium: YAG lasers in urology: insights from the FDA MAUDE database